Literature DB >> 9813138

Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4.

H Schneider1, P L Schwartzberg, C E Rudd.   

Abstract

CTLA-4 and CD28 are differentially expressed on T-cells. They bind to a common ligand B71/2 (CD80/86), however with different avidities. Unlike CD28 which augments the T-cell response, CTLA-4 operates predominately as a negative regulator of T-cell proliferation. The mechanism by which CTLA-4 can generate these intracellular signals is unclear. Little is known regarding the identity of the protein-tyrosine kinase(s) responsible for CTLA-4 phosphorylation and thus creating conditions for the reported binding to PI 3-kinase and the protein tyrosine phosphatase SHP-2. In this study, we demonstrate that Rlk (resting lymphocyte kinase) is capable of phosphorylating CTLA-4 at the YVKM motif. Consistent with this finding, Rlk is capable of providing conditions for the binding of the SH2 domains of PI 3-kinase to the receptor. CTLA-4 is therefore the first known substrate for Rlk suggesting the possibility that this kinase may participate in CTLA-4 function. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9813138     DOI: 10.1006/bbrc.1998.9559

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Nat Rev Immunol       Date:  2011-11-25       Impact factor: 53.106

Review 2.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

3.  Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.

Authors:  Melanie Stumpf; Xuyu Zhou; Shunsuke Chikuma; Jeffrey A Bluestone
Journal:  Eur J Immunol       Date:  2014-04-15       Impact factor: 5.532

4.  Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.

Authors:  Chao Yu; Andreas F-P Sonnen; Roger George; Benoit H Dessailly; Loren J Stagg; Edward J Evans; Christine A Orengo; David I Stuart; John E Ladbury; Shinji Ikemizu; Robert J C Gilbert; Simon J Davis
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

5.  Txk, a nonreceptor tyrosine kinase of the Tec family, is expressed in T helper type 1 cells and regulates interferon gamma production in human T lymphocytes.

Authors:  J Kashiwakura; N Suzuki; H Nagafuchi; M Takeno; Y Takeba; Y Shimoyama; T Sakane
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

6.  RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.

Authors:  K Rajagopal; C L Sommers; D C Decker; E O Mitchell; U Korthauer; A I Sperling; C A Kozak; P E Love; J A Bluestone
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

Review 7.  Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Authors:  Helga Schneider; Christopher E Rudd
Journal:  Front Immunol       Date:  2014-12-04       Impact factor: 7.561

Review 8.  Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Authors:  Nikolaos Patsoukis; Jessica D Weaver; Laura Strauss; Christoph Herbel; Pankaj Seth; Vassiliki A Boussiotis
Journal:  Front Immunol       Date:  2017-04-11       Impact factor: 7.561

Review 9.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 10.  Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases.

Authors:  Monika C Brunner-Weinzierl; Holger Hoff; Gerd-R Burmester
Journal:  Arthritis Res Ther       Date:  2004-03-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.